Our data provide evidence of pharmacogenetic associations between variants in the MMP9 and MMP12 genes and treatment for a variety of these cardiovascular outcomes: MMP9 R668Q variant for both combined CHD and stroke; MMP9 R279Q variant for the combined CVD outcome; and MMP12 N122S variant for CHD, combined CHD, combined CVD, and ACM. The gene discussed is MMP9; the disease is coronary artery disorder.